Tango Therapeutics, Inc.
TNGX
Rang în acțiuni
#4542
Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and... Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and development of innovative cancer treatments. Their primary therapeutic candidate, TNG908, is a synthetic lethal small molecule designed to inhibit protein arginine methyltransferase 5 (PRMT5). This compound is currently being advanced as a potential therapy for cancers characterized by methylthioadenosine phosphorylase (MTAP) deletions. Additionally, their pipeline includes an Ubiquitin-specific protease 1 (USP1) inhibitor targeting BRCA1 or BRCA2-mutant cancers, and a program known as 'Target 3' which addresses STK11-mutant cancers. Tango Therapeutics maintains a strategic alliance with Gilead Sciences, Inc., focused on the identification, advancement, and commercialization of a diverse array of cancer therapies. Established in 2017, the company's operations are headquartered in Cambridge, Massachusetts.
Preț acțiune
$27.18
Ultima sincronizare: 2026-07-31
Capitalizare de piață
$3.38B
Schimbare (1 zi)
-1.41%
Schimbare (1 an)
202.34%
Țară
US
Tranzacționează Tango Therapeutics, Inc. (TNGX)
Categorie
Healthcare
Istoricul spliturilor pentru Tango Therapeutics, Inc. (TNGX)
Acțiunea Tango Therapeutics, Inc. (simbol: TNGX) a trecut printr-un total de 0 splituri.
Cel mai recent split a avut loc pe Oct 21, 2026.
O acțiune TNGX cumpărată înainte de Oct 21, 2026 este echivalentă astăzi cu 0 acțiuni TNGX.
Cel mai recent split a avut loc pe Oct 21, 2026.
O acțiune TNGX cumpărată înainte de Oct 21, 2026 este echivalentă astăzi cu 0 acțiuni TNGX.
Listă splituri acțiuni
| An | Split | Multiplu | Multiplu cumulativ |
|---|---|---|---|
| Nu sunt suficiente date pentru perioada selectată. | |||
Splituri pentru companii similare sau competitori
| Companie | Număr total de splituri | Multiplu cumulativ | Țara |
|---|---|---|---|
| 1 | x2 |
US
|
|
| 0 | - |
US
|
|
| 1 | x3 |
AU
|
|
| 0 | - |
CH
|
|
| 0 | - |
NL
|
